TRVN - Trevena, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.848
-0.032 (-3.65%)
At close: 4:00PM EDT

0.820 -0.03 (-3.30%)
After hours: 5:08PM EDT

Stock chart is not supported by your current browser
Previous Close0.880
Open0.890
Bid0.820 x 900
Ask0.850 x 1100
Day's Range0.825 - 0.910
52 Week Range0.760 - 3.578
Volume5,101,004
Avg. Volume3,445,981
Market Cap64.518M
Beta (3Y Monthly)0.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena
    Zacks3 days ago

    The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena

    The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena

  • Benzinga3 days ago

    The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

    Here's a roundup of top developments in the biotech space over the last 24 hours. Amid the market mayhem, no biotech or medical device companies made it to 52-week highs. Down In The Dumps (Biotech stocks ...

  • FDA advisory committee recommends not approving Trevena pain drug
    American City Business Journals3 days ago

    FDA advisory committee recommends not approving Trevena pain drug

    The FDA's Anesthetic and Analgesic Drug Products Advisory Committee voted eight against, and seven in favor of, supporting the approval of Trevena's new drug application.

  • Reuters4 days ago

    Trevena's opioid painkiller fails to get FDA panel backing

    Trevena Inc's opioid injection for managing acute pain failed to win the backing of an advisory panel to the Food and Drug Administration on Thursday, against the backdrop of opioid addiction in the United States reaching epidemic proportion. The panel voted 8-7 against approving the treatment which is administered in hospitals and ambulatory surgery centers and aims to manage acute pain in patients for whom an intravenous opioid is necessary.

  • Benzinga5 days ago

    AcelRx Shares React Positively To FDA Committee Briefing On Painkiller Candidate Dsuvia

    The briefing document released by FDA's Anesthetic and Analgesic Drug Products Advisory Committee, which is evaluating AcelRx Pharmaceuticals Inc (NASDAQ: ACRX)'s new drug application for Dsuvia, said the dose and dosage regimen appear effective in the drug's proposed population and reasonably safe in the context of existing opioid therapy. The 30-mcg of sufentanil sublingual tablets are intended to treat moderate-to-severe acute pain that requires an opioid analgesic and for which alternative treatments are inadequate.

  • Trevena’s stock slides after safety concerns raised about new drug candidate
    American City Business Journals5 days ago

    Trevena’s stock slides after safety concerns raised about new drug candidate

    Trevena’s stock closed down 64 percent Tuesday after Food and Drug Administration review staff raised potential safety concerns about the Chesterbrook, Pa., biopharmaceutical company’s lead drug candidate. The new drug candidate for severe-to-moderate pain in patients in need of an intravenous opioid treatment has the proposed brand name Olinvo and the active ingredient oliceridine. In background materials prepared for the agency’s Anesthetic and Analgesic Drug Products Advisory Committee meeting to review Trevena’s application on Oct. 11, FDA staff's assessment says oliceridine has “an abuse potential, overdose potential and ability to produce physical dependence that is similar to other (opioids).” The published staff report sent the company’s stock down 64 percent to $1.07 per share.

  • Reuters6 days ago

    FDA staff raises safety issues over Trevena opioid injection

    Trevena Inc's opioid injection to treat acute pain could be abused and potentially lead to overdose, staff reviewers of the U.S. Food and Drug Administration said on Tuesday, sending the drugmaker's shares down 66 percent. The treatment, oliceridine, aims to manage moderate-to-severe acute pain in adult patients for whom an intravenous opioid is necessary and the injection should be administered in hospitals and ambulatory surgery centers.

  • New CEO takes over at Trevena
    American City Business Journals14 days ago

    New CEO takes over at Trevena

    Trevena Inc. completed its previously announced leadership transition on Monday. Carrie L. Bourdow, formerly the Chesterbrook, Pa., biopharmaceutical company's executive vice president and chief operating officer, has assuming the role of president and CEO and joined Trevena's board of directors. Maxine Gowen, the company’s founding president and CEO, has retired.

  • 3 Biotech Stocks With Rising Estimates in the Past Month
    Zacks17 days ago

    3 Biotech Stocks With Rising Estimates in the Past Month

    The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.

  • Implied Volatility Surging for Trevena (TRVN) Stock Options
    Zacks20 days ago

    Implied Volatility Surging for Trevena (TRVN) Stock Options

    Trevena (TRVN) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Analysts Bet Trevena’s (TRVN) Pain Management Drug Will Get FDA Approval
    SmarterAnalyst27 days ago

    Analysts Bet Trevena’s (TRVN) Pain Management Drug Will Get FDA Approval

    Trevena (NASDAQ:TRVN). Trevena could be on track to win FDA approval for its lead candidate oliceridine, a potential treatment for moderate to severe acute pain. While the advisory committee's vote doesn't automatically mean the FDA will decide on oliceridine in the same way, it should be a pretty good predictor.

  • Associated Press2 months ago

    Trevena: 2Q Earnings Snapshot

    The Chesterbrook, Pennsylvania-based company said it had a loss of 13 cents per share. The biopharmaceutical company posted revenue of $2.5 million in the period. The company's shares closed at $1.49. ...

  • Investopedia3 months ago

    Trevena (TRVN): Key Catalysts Coming Into View

    Trevena (NASDAQ: TRVN) is expecting an FDA decision on its pain drug oliceridine on November 2. Furthermore, the FDA has informed the company that it intends to convene an advisory committee meeting to discuss the oliceridine filing (likely in September), which could be a catalyst for shares if positive. Wall Street analysts continue to believe Olinvo will likely be approved by the FDA based on the draft guidelines and two positive pivotal Phase 3 APOLLO studies and ATHENA safety study.

  • Are New Drug Approvals Right Around the Corner for Trevena (TRVN) and Array Biopharma (ARRY)?
    SmarterAnalyst4 months ago

    Are New Drug Approvals Right Around the Corner for Trevena (TRVN) and Array Biopharma (ARRY)?

    Trevena (NASDAQ:TRVN) and Array Biopharma (NASDAQ:ARRY) investors could be celebrating soon enough, should these two drug makers achieve that triumphant FDA approval at the close of a winding biotech road. Between Trevena's opioid asset oliceridine, designed as an intravenous treatment of severe acute pain, and Array's BRAF-mutant melanoma combination therapy candidate encorafenib + binimetinib getting close to final FDA verdicts, two bulls at Cowen are out shedding light on the opportunity ahead.

  • Best High Growth NasdaqGS Stocks This Week
    Simply Wall St.4 months ago

    Best High Growth NasdaqGS Stocks This Week

    Investors seeking to increase their exposure to growth should consider companies such as Trevena and Redfin. Analysts are generally optimistic about the future of these stocks, based on how muchRead More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of TRVN earnings conference call or presentation 3-May-18 12:00pm GMT

    Q1 2018 Trevena Inc Earnings Call

  • Associated Press5 months ago

    Trevena: 1Q Earnings Snapshot

    The Chesterbrook, Pennsylvania-based company said it had a loss of 14 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of TRVN earnings conference call or presentation 7-Mar-18 1:00pm GMT

    Q4 2017 Trevena Inc Earnings Call

  • GuruFocus.com7 months ago

    3 Stocks Move Wednesday

    Stocks advance on stronger-than-expected results

  • Associated Press7 months ago

    Trevena reports 4Q loss

    On a per-share basis, the Chesterbrook, Pennsylvania-based company said it had a loss of 24 cents. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Trevena Inc (NASDAQ:TRVN): When Will It Breakeven?
    Simply Wall St.7 months ago

    Trevena Inc (NASDAQ:TRVN): When Will It Breakeven?

    Trevena Inc’s (NASDAQ:TRVN): Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The US$120.24M market-cap company’s lossRead More...

  • 7 High-Risk, High-Reward Stocks to Buy Now
    InvestorPlace9 months ago

    7 High-Risk, High-Reward Stocks to Buy Now

    The company will next report results on Feb. 9, before the bell. Analysts are looking for earnings of 44-cents-per-share on revenues of $4 billion. When the company last reported on Nov. 10, a loss of 33-cents-per-share beat estimates by 10 cents on a 1.8% decline in revenues.